StandardAero (NYSE: SARO) announced results today for the three months ended September 30, 2025 ("Third Quarter 2025").

Revenue reached $8.5 million, up 90% year over year; nine-month revenue totaled $25.8 million, representing 132% of full-year ...

Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming ...